Articles Published in 2013

NIH awards $33m grant to Banner Alzheimer's Institute, study planned

Friday, September 20, 2013 11:14 AM

Banner Alzheimer's Institute (BAI) has announced a major prevention trial to evaluate a treatment in cognitively healthy older adults at the highest known genetic risk for developing Alzheimer's disease at older ages. An NIH grant, expected to total $33.2 million, will support this research.

More... »

NYSCF an associate member of NYGC

Friday, September 20, 2013 11:07 AM

The New York Stem Cell Foundation (NYSCF) has become an associate member of The New York Genome Center (NYGC), joining NYGC's growing consortium of 16 research and clinical institutions, all working together in new ways to utilize genomic data for better detection, treatment, and prevention of disease.

More... »

BioTime, Jade Therapeutics ink deal

Friday, September 20, 2013 10:52 AM

BioTime, a biotechnology company that develops and markets products in regenerative medicine, has signed an exclusive sublicense agreement with Jade Therapeutics, a Salt Lake City, Utah-based developer of ophthalmic sustained-release drug delivery platforms. This new agreement supersedes the previously announced sublicense and supply agreements and expands the licensed field of use to include certain additional uses, such as BioTime’s HyStem hydrogel technology for the delivery of all potential therapeutic molecules to the human eye. Excluded from the licensed field of use is the HyStem technology for the delivery of cells with or without any molecules necessary for the therapeutic benefit of those cells, for use in making punctal plugs, for diagnostic and research reagents and for non-human applications.

More... »

Trifecta Clinical, SAFE-BioPharma partner

Friday, September 20, 2013 10:37 AM

Trifecta Clinical, a global clinical technology solutions provider, has partnered with SAFE-BioPharma to implement the SAFE-BioPharma digital identity and signature standard across its application platforms. The digital identity and signature standard provides standardized, high-assurance identity trust for cyber-transactions across the biopharmaceutical and healthcare sectors. This will accelerate the adoption of standards-based identity management, enhancing security, quality and compliance. The company also joined SAFE-BioPharma Association’s Vendor Partner Program.

More... »

TrialReach launches new platform giving patients greater access to clinical trials

Friday, September 20, 2013 09:51 AM

TrialReach, a London-based web site that connects patients to clinical trials worldwide, has launched a new platform that dramatically reduces the time and costs required to find clinical trial participants.

More... »

BBK Worldwide forms regional ‘hub’ leaders for its Patient Recruitment Global Alliance

Friday, September 20, 2013 09:47 AM

Established more than a decade ago as a think tank for global enrollment strategies, the BBK Worldwide Patient Recruitment Global Alliance has grown to represent more than 50 companies around the world. These companies work in collaboration to support clinical trial recruitment and retention. Alliance founder BBK now has announced the creation of regional hub leaders to further enhance its ability to evaluate and train international consulting companies in the marketing discipline of patient recruitment, a necessary step to ensure culturally relevant and seamlessly integrated global offerings.

More... »

iCTRS, ViS Research partner for more efficient site selection process

Wednesday, September 18, 2013 03:29 PM

inVentiv Clinical Trial Recruitment Solutions (iCTRS), offering solutions to overcome the costly obstacles that delay clinical trials, has partnered with ViS Research, an online feasibility platform using interactive visualizations, to revolutionize and speed the antiquated system of clinical trial site evaluation.

More... »

H3 Biomedicine, Selvita collaborate

Wednesday, September 18, 2013 01:41 PM

H3 Biomedicine, a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have are collaborating to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

AstraZeneca, Daiichi Sankyo launch reflux esophagitis iPhone app

Wednesday, September 18, 2013 01:36 PM

Daiichi Sankyo and AstraZeneca are working to educate the public about reflux esophagitis through a campaign entitled Do you experience heartburn or acid reflux? The awareness building effort seeks to ensure an accurate understanding of the symptoms of reflux esophagitis and how they affect the daily lives of patients. The campaign incorporates a variety of media, featuring TV commercials, an iPhone app and a website to encourage patients to seek the appropriate treatment and take control of their lives.

More... »

Medtronic opens Ireland Innovation Center

Wednesday, September 18, 2013 12:44 PM

Medtronic, a Minneaplis, Minn.-based medical technology provider, has opened a new Customer Innovation Center (CIC) in Galway, Ireland, providing state-of-the-art facilities for physicians and Medtronic engineers to develop new therapies that will improve clinical outcomes, provide economic value and increase access to quality healthcare for patients around the world.

More... »